Bausch + Lomb Completes Enrollment of first Phase 3 Study for Nov03 (perfluorohexyloctane)
01/20/2021
LAVAL, Quebec, and HEIDELBERG, Jan. 20 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
12/08/2020
Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
- ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA)
- Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial
- Topline data expected in 2nd half 2021
Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
11/25/2020
LAVAL, Quebec, Nov. 24, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD). Enrollment of the first Phase 3 study is currently underway and has reached 85% of its enrollment goal.
AFT introduces Novatear+Omega-3 eye drop in Australia
10/19/2020
ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3.
Development Update on CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
07/24/2020
Heidelberg – July 23, 2020 – Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today provided a development update on its investigational water-free and preservative-free drug CyclASol®.
Bausch Health licenses Novaliq’s NOV03 investigational treatment for dry eye disease associated with Meibomian gland dysfunction
12/20/2019
LAVAL, Quebec, and HEIDELBERG, Germany, Dec. 20, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
Season’s Greetings!
12/18/2019
Thank you for your continued commitment. We wish you and your family a happy holiday season and best wishes for a healthy New Year. See you in 2020 ?
Novaliq and Jiangsu Hengrui Medicine announce a strategic collaboration for the investigational products NOV03 and CyclASol® in China
11/08/2019
- Jiangsu Hengrui Medicine secures exclusive rights to develop, manufacture, and commercialize NOV03 and CyclASol® in China.
- NOV03 (perfluorohexyloctane) is a first-in-class investigational drug with a novel mode of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
- CyclASol® (0.1% cyclosporine A in EyeSol®) is an anti-inflammatory and immunomodulating investigational drug developed for the treatment of aqueous deficient DED.
- Novaliq is eligible to receive upfront and milestone payments of up to $165 million plus royalties
New Video: Novaliq Targeting Phenotypes in Dry Eye Disease Interview at OIS@ASCRS 2019
09/20/2019
Christian Roesky, PhD, CEO of Novaliq was interviewed by Ehsan Sadri, MD, FACS, FAAO and discussed how to treat Dry Eye Disease in the future based on the pivotal clinical trial results of NOV03 and CyclASol
Novaliq named Finalist in “Clinical Trial Result of the Year” category of the LifeStars Awards 2019
09/10/2019
Heidelberg, Germany – September 10, 2019 – Novaliq is pleased to announce that it has been recognised in the finalist roster of the Clinical Trial of the Year at the 2019 Lifestars AwardsTM.
New Video: Novaliq at OIS@ASCRS
05/29/2019
Based on the new pivotal clinical trial results of NOV03 and CyclASol which were presented at the ASCRS, rethinking DED treatment becomes a reality.
New Video: Novaliq at ASCRS
05/28/2019
Christian Roesky discusses how the company is rethinking DED therapy
Novaliq and BLP Management Group Established New Company, Betaliq Inc., to Leverage EyeSol Technology to Treat Glaucoma
04/25/2019
- Betaliq is developing ophthalmic ß-blockers for the treatment of glaucoma using Novaliq’s waterfree EyeSol® technology
- Betaliq successfully collected proceeds in a Series A round
New OIS-podcast, Episode 215
04/11/2019
Listen in to Bernhard Günther, founder of Novaliq, about the company’s trailblazing start and promising future
Novaliq named Finalist in “Clinical Trial Result of the Year” category of the Clinical & Research Excellence Awards CARE 2019
02/26/2019
- Novaliq is recognized for its SEECASE clinical trial results of NOV03 demonstrating unprecedented sign and symptom improvements for Dry Eye Disease (DED) patients while offering an excellent safety profile
- NOV03 is potentially the first drug targeting the key underlying cause of evaporative DED, the leading reason for this undertreated disease that impacts visual function
New Video: Novaliq discussed at the Hawaiian Eye conference
01/25/2019
Video: New water-free dry eye drop shows promising clinical results
New Video: Novaliq at Biotech Showcase
01/17/2019
New Video: Novaliq making headway with its water-free eye drops. Have a look at the video:
Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations
12/24/2018
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators. As part of this focus, Nicox has entered into a research collaboration with Novaliq GmbH for the development of novel topical ophthalmic formulations of Nicox’s NO-donating PDE5 inhibitors based on Novaliq’s water-free enabling EyeSol® technology, for lowering intraocular pressure (IOP).
Season’s Greetings!
12/19/2018
Thank you for your commitment and support in 2018. We wish you and your family a terrific Holiday Season and a good start to a healthy and successful New Year. See you in 2019 ?
New Video: Novaliq at OIS
12/11/2018
New Video: Novaliq presented positive topline data for two drugs in late-stage clinical trials. Have a look at the OIS video: